Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acurx Pharmaceuticals, LLC*

0.4573
-0.1947-29.86%
Post-market: 0.46980.0125+2.73%19:52 EST
Volume:1.18M
Turnover:548.26K
Market Cap:8.91M
PE:-0.43
High:0.5000
Open:0.4605
Low:0.4500
Close:0.6520
Loading ...

Company Profile

Company Name:
Acurx Pharmaceuticals, LLC*
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
4
Office Location:
259 Liberty Avenue,Staten Island,New York,United States
Zip Code:
10305
Fax:
- -
Introduction:
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Directors

Name
Position
David P. Luci
President and Chief Executive Officer, Director
Robert J. DeLuccia
Executive Chairman, Director
Carl V. Sailer
Director
Jack H. Dean
Director
James Donohue
Director
Joseph C. Scodari
Director
Thomas Harrison
Director

Shareholders

Name
Position
David P. Luci
President and Chief Executive Officer, Director
Robert G. Shawah
Chief Financial Officer
Robert J. DeLuccia
Executive Chairman, Director